Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs. The cap will reduce out-of-pocket spending for potentially millions of older Americans in Medicare Part D, which covers pharmacy or mail-order ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden administration announced Friday.

The median wait time between referral and appointment was 34 days, and 18 percent of patients waited more than 90 days, the study found.

A recent study reveals that Medicare Advantage plans, despite costing more, do not provide significantly more dental, vision, and hearing benefits compared to traditional Medicare. The research highli

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

Part C is a bundled plan that you would call Medicare Advantage. It is an opportunity that you have to choose what kind of Medicare program you want. You can pick your doctor as long as he or she is a Medicare-eligible doctor and in your health system.

Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

The Trump administration inherited some big health policy headaches on Monday. And the nature of federal rules means it can't start from scratch on key questions about surprise billing, coverage of GLP-1s and prescribing controlled substances.

Clover Health Investments' AI technology and unique positioning in the healthcare market set them apart from competitors. Read more on CLOV stock here.

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new rule that would expand Medicare and Medicaid coverage for enrollees seeking prescription drugs popularized in recent years as weight-loss expedients.